US FDA Approves ONTRUZANT® (trastuzumab-dttb), Samsung Bioepis’ First Oncology Medicine in the United States
21.1.2019 02:38:00 EET | Business Wire | Press release
Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved ONTRUZANT® (trastuzumab-dttb), a biosimilar referencing HERCEPTIN® 1 (trastuzumab), across all eligible indications, namely adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease. Please see Boxed Warnings and Important Safety Information for ONTRUZANT® below.
ONTRUZANT® is Samsung Bioepis’ first oncology biosimilar to receive FDA approval, and will be marketed and distributed in the United States (US) by Merck, which is known as MSD outside of the US and Canada.
“For many cancer patients in the US, battling cancer has not only been a health issue, but a considerable financial burden brought on by cancer treatment. Biosimilars are intended to be lower cost, high-quality treatment options that have the potential to alleviate such burden. We sincerely hope our trastuzumab biosimilar will do exactly that,” said Sang-Jin Pak, Senior Vice President and Head of Commercial Division, Samsung Bioepis. “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening the availability of approved treatments for cancer patients across the US.”
ONTRUZANT® was also approved by the European Commission (EC) in November 2017, and has since been launched in a growing number of European countries.
About ONTRUZANT (trastuzumab-dttb)
ONTRUZANT is indicated
for adjuvant treatment of HER2-overexpressing node-positive or
node-negative (ER/PR-negative or with one high-risk feature*) breast
cancer:
- As part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel
- With docetaxel and carboplatin
- As a single agent following multi-modality anthracycline-based therapy
Select patients for therapy based on an FDA-approved companion
diagnostic for a trastuzumab product.
* High-risk is defined as
ER/PR positive with one of the following features: tumor size >2 cm, age
<35 years, or tumor grade 2 or 3.
ONTRUZANT is indicated:
- In combination with paclitaxel for the first line treatment of HER2-overexpressing metastatic breast cancer
- As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease
Select patients for therapy based on an FDA-approved companion
diagnostic for a trastuzumab product.
ONTRUZANT is indicated, in
combination with cisplatin and capecitabine or 5-fluorouracil, for the
treatment of patients with HER2 overexpressing metastatic gastric or
gastroesophageal junction adenocarcinoma, who have not received prior
treatment for metastatic disease.
Select patients for therapy based
on an FDA-approved companion diagnostic for a trastuzumab product
Select Important Safety Information
Cardiomyopathy
- ONTRUZANT administration can result in sub-clinical and clinical cardiac failure manifesting as congestive heart failure and decreased left ventricular ejection fraction with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue ONTRUZANT for cardiomyopathy.
Infusion Reactions; Pulmonary Toxicity
- Administration can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of administration. Discontinue ONTRUZANT for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.
Embryo-Fetal Toxicity
- Exposure to ONTRUZANT during pregnancy can result in oligohydramnios in some cases complicated by pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception
Exacerbation of Chemotherapy-Induced Neutropenia
- In randomized, controlled clinical trials, the per-patient incidences of NCI-CTC Grade 3-4 neutropenia and of febrile neutropenia were higher in patients receiving trastuzumab products in combination with myelosuppressive chemotherapy as compared to those who received chemotherapy alone. The incidence of septic death was similar among patients who received trastuzumab and those who did not
Most Common Adverse Reactions
- The most common adverse reactions for trastuzumab products in breast cancer were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia
- The most common adverse reactions for trastuzumab products in metastatic gastric cancer were neutropenia, diarrhea, fatigue, anemia, stomatitis, weight loss, upper respiratory tract infections, fever, thrombocytopenia, mucosal inflammation, nasopharyngitis, and dysgeusia
These are not all of the risks associated with ONTRUZANT ® . For additional information on ONTRUZANT® indications, as well as Important Safety Information related to its use, including Boxed WARNINGS, please see the ONTRUZANT® Prescribing Information HERE
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung
Bioepis is a biopharmaceutical company committed to realizing healthcare
that is accessible to everyone. Through innovations in product
development and a firm commitment to quality, Samsung Bioepis aims to
become the world's leading biopharmaceutical company. Samsung Bioepis
continues to advance a broad pipeline of biosimilar candidates that
cover a spectrum of therapeutic areas, including immunology, oncology,
ophthalmology and hematology. Samsung Bioepis is a joint venture between
Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.
# # #
_____________________________
1 HERCEPTIN ® is a registered trademark of Genentech Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190120005023/en/
Contact information
Mingi Hyun
+82-31-8061-1594
mingi.hyun@samsung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bridger Photonics Posts Record Year as Operators Turn to Trusted Emissions Intelligence4.2.2026 14:20:00 EET | Press release
Bridger Photonics (“Bridger”) closed its strongest year in company history last year, marked by record asset coverage, record revenue, and global adoption of its methane emissions data and intelligence across multiple continents and the entire oil and natural gas value chain. Bridger’s momentum reflects a clear shift in how operators choose to manage emissions: away from legacy and weather-limited approaches and toward entire asset coverage with data they can trust. Bridger continues to lead the methane detection space—growing existing customers and attracting new ones. Bridger has competitively displaced 32 customers from other aerial technologies, driven by deep industry expertise, proven data reliability and actionability, the ability to operate across challenging conditions and seasons, close coordination with ground crews, and a white-glove service model designed around operator needs. Customers across onshore production, midstream, LNG, and offshore operations are increasingly re
Macrobond Launches Macrobond Amplify, A New Standard for Interactive Financial Research4.2.2026 14:00:00 EET | Press release
Macrobond, the global platform for macroeconomic and financial data, announced the launch of Macrobond Amplify, a browser-based research distribution tool that enables economists and analysts to deliver rich, interactive content to their consumers at scale. Amplify empowers analysts and research teams to move beyond static charts and PDFs, delivering interactive, explorable insights that build trust, foster collaboration, and drive better decision-making. With Amplify, research teams can publish interactive, auditable research models that clients can explore directly through charts and dynamic visualizations. By sharing a simple link, Amplify users can distribute their research at scale with both internal partners and clients. “As the research industry evolves, analysts and economists face growing pressure to ensure their work reaches the right audiences, shows transparency, and demonstrates the rigour behind their thinking,” says Dan Seal, Chief Product Officer at Macrobond. “Amplify
Registrar Corp Acquires TechniCAL and Becomes the Global Compliance Leader in Shelf-stable Packaged Foods Safety4.2.2026 14:00:00 EET | Press release
Registrar Corp, the world’s largest food and beverage regulatory compliance provider, today announced its acquisition of TechniCAL, the world’s leading independent Process Authority for low-acid and acidified foods. Registrar Corp is a Paine Schwartz Partners portfolio company. Consumer demand for convenience and longer product life without refrigeration has driven rapid growth in shelf-stable foods and beverages, with packaging innovations extending beyond cans and glass jars to formats such as retort pouches and cartons. Ensuring products in these various packaging formats are safe from harmful microorganisms is critical to public health and required by the U.S. FDA. Together, Registrar Corp and TechniCAL provide the industry’s most complete solution, combining proven scientific expertise, regulatory knowledge, training, and advanced thermal testing. “TechniCAL is world renowned for its Process Authority expertise and advanced testing technologies assuring compliant thermal processin
Kinaxis Announces Intention to Maximize Size of Normal Course Issuer Bid4.2.2026 14:00:00 EET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) today announces that it intends to amend its current normal course issuer bid (the “NCIB”) to increase the number of its common shares (the “Shares”) that may be repurchased from 1,403,042, representing 5% of the Company’s issued and outstanding Shares as at October 31, 2025, to approximately 2,799,843, representing 10% of the Company’s “public float” as at October 31, 2025, which is the maximum allowable under the rules of the Toronto Stock Exchange (the “TSX”). The Company has already invested US$54 million under its current NCIB. At the average price paid to date for the Shares under the current NCIB, repurchasing 10% of the Shares would represent an additional investment of approximately US$284 million. “There is a fundamental misunderstanding of the opportunities and threats from generative and agentic AI to mission-critical enterprise software, like ours, that solves deeply complex problems and enables highly consequential dec
Morgan Stanley Inclusive & Sustainable Ventures Hosts Global Demo Day, Opens Applications for Next Cohort4.2.2026 14:00:00 EET | Press release
Morgan Stanley (NYSE: MS) today is hosting its annual global Inclusive & Sustainable Ventures (MSISV) Demo Day, with startups and nonprofits participating from across the Americas, Europe, the Middle East and Africa (EMEA). The organizations will pitch over 300 investors, as well as potential business partners and customers. Over the past five months, MSISV has supported 29 startups and four nonprofits through an intensive accelerator program, providing them with capital, a tailored curriculum, mentorship opportunities and business-growth resources from Morgan Stanley’s ecosystem of internal and external partners. “With founders spanning 10 countries and 13 industries, our Morgan Stanley Inclusive & Sustainable Ventures cohort underscores the potential of innovators globally to bring disruptive solutions for business and society to market,” said Jessica Alsford, Morgan Stanley Chief Sustainability Officer. “We are eager to watch as these founders continue to scale with the backing of o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom